Hemofarm, the regional leader in the pharmaceutical industry, rounded off the 10th anniversary of its operations within the framework of the STADA international concern, record production levels, with investments worth tens of millions of euros and the enormous trust of customers in more than 38 countries on three continents.
The formal reception, organised for the company’s friends, partners and associates, provided a good opportunity to summarise the annual results of this pharmaceutical giant. The end of the year also saw Hemofarm become STADA’s hub for Southeast Europe and open a new Quality building, which is the centre of the most up-to-date equipment and the best-educated experts.
“This is not only confirmation of the continuation of STADA’s investment in its business in Serbia, but rather a huge argument that the generic industry is not a copy, but rather an innovator in the production of accessible, safe and high-quality products that are exclusively in the function of serving the nation’s health,” said Ronald Seeliger, Hemofarm CEO and Vice President of the STADA Group for Southeast Europe.
